BioCryst Pharmaceuticals (BCRX) Set to Announce Earnings on Wednesday

BioCryst Pharmaceuticals (NASDAQ:BCRX) is expected to be announcing its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect the company to post earnings of $0.0919 per share and revenue of $165.67 million for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 8:30 AM ET.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.30 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.15 by $0.15. The firm had revenue of $218.25 million during the quarter, compared to the consensus estimate of $183.28 million. The business’s revenue was up 33.6% compared to the same quarter last year. During the same period last year, the business earned $0.15 earnings per share. On average, analysts expect BioCryst Pharmaceuticals to post ($2.28) EPS for the current fiscal year and $0.72 EPS for the next fiscal year.

BioCryst Pharmaceuticals Price Performance

Shares of NASDAQ:BCRX opened at $8.10 on Wednesday. BioCryst Pharmaceuticals has a 1 year low of $6.23 and a 1 year high of $11.22. The company’s 50 day simple moving average is $8.71 and its 200 day simple moving average is $8.71.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on BCRX shares. JPMorgan Chase & Co. raised their target price on BioCryst Pharmaceuticals from $12.00 to $13.00 and gave the company a “neutral” rating in a report on Wednesday, September 30th. Royal Bank Of Canada cut BioCryst Pharmaceuticals from an “outperform” rating to a “sector perform” rating and lowered their price target for the stock from $13.00 to $11.00 in a report on Thursday, September 10th. Wall Street Zen raised BioCryst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday. Needham & Company LLC restated a “buy” rating and set a $16.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Tuesday, September 8th. Finally, Weiss Ratings lowered BioCryst Pharmaceuticals from a “hold (c)” rating to a “sell (d-)” rating in a research note on Tuesday, September 22nd. Six research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $19.44.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a biotechnology company focused on developing and commercializing oral medicines for rare and serious diseases. The company uses structure-based drug design and small-molecule research to develop therapies intended to address conditions with limited treatment options.

BioCryst’s primary commercial product is Orladeyo (berotralstat), an oral medication used to prevent hereditary angioedema attacks in adults and pediatric patients aged 12 and older. The company also maintains a pipeline of investigational therapies for complement-mediated diseases and other rare disorders, including programs designed to inhibit components of the complement system.

Founded in 1986 and headquartered in Durham, North Carolina, BioCryst has historically conducted research and commercial activities in the United States and worked with international partners to make its products available in additional markets.